"Of course (I'd like to fight him)," says St-Pierre of Askren. "He's a good fighter, undefeated, and yes, if he comes, I'll fight him. No problem."
"Bring him in; I'll fight everyone. I am the champion, and I have no choice, so it's no problem. I'm not afraid."
Askren, who finished out his contract with Bellator with a successful title defense to Andrey Koreshkov in July, mulled retirement before deciding it was 'time for some new challenges.' Although UFC president Dana White once characterized Askren as human Ambien, the promotion is expected to make some sort of offering in the near future. As for when, it largely depends on the extenuating circumstances involving Bellator's matching period with Askren. Once the matching period has ended, Askren becomes a true free agent, allowed to sign with whomever regardless of the terms.
With no fight on the docket, Askren has been keeping busy competing in the newly formed Agon Wrestling Championships, most recently outpointing two-time NCAA champion and four-time All-American Quentin Wright in the promotion's inaugural event on Oct. 27. St-Pierre, who has a bit more on his plate, defends his welterweight title to Johny Hendricks on Nov. 16 at UFC 167 in Las Vegas, Nevada.
Knapp says no. After a report stated the UFC had plans on creating a women's strawweight (115lbs) division, Invicta FC CEO Shannon Knapp says it's not happening.
#6 Seo Hee Ham vs. #12 Sadae Numata (For Atomweight title) Both of these girls (woman for Numata, I mean she's FORTY ONE, according to Sherdog) would be welcome additions to Invicta's 105 division. In seems Invicta isn't keen on a Penne/Waterson rematch, so soon. The winner of this fight, could be next for Waterson.
Numata missed weight for her last fight, so it'll be interesting to see what happens if she misses weight again. It can't be easy cutting weight as not only a woman, but also a 41 year old woman. This is a very winnable fight for Numata.
#10 Mizuki Inoue vs #11 Emi Fujino (Strawweight Semi-Final #1) Inoue drew first in the random draw and got Fujino. Fujino is a tough fighter, but she loses to the best, and Inoue is going to be a star. Inoue has already fought girls on Fujino's level, such as Invicta fighters, Alex Chambers, Bec Hyatt and Ayaka Hamasaki, beating Chambers and Hyatt. She had the best debut for a Japanese fighter in America in a long, long time (Horiguchi made an emphatic debut against Dustin Pague too).
Foes of Obamacare are excitedly citing a rash of new stories claiming untold Americans are “losing” their insurance, as CBS News’ Norah O’Donnell puts it. One of them is this NBC News story, which reports that “millions of Americans are getting or are about to get cancellation letters for their health insurance under Obamacare, say experts, and the Obama administration has known that for at least three years.”
Is YouTube a driver for social movements like Occupy Wall Street?
PUBLIC RELEASE DATE:
29-Oct-2013
[
| E-mail
]
Share
Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, October 29, 2013Social media such as YouTube videos provide a popular and flexible venue for online activism. How two different social protest movementsOccupy Wall Street and the Proposition 8 same sex marriage initiativeutilized YouTube, and their success in engaging activists are explored in an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cyberpsychology, Behavior, and Social Networking website.
Emily Vraga, PhD and coauthors from George Mason University (Fairfax, VA), Georgetown University (Washington, DC), University of Wisconsin-Madison, and University of Southern California (Los Angeles, CA) emphasize an important advantage of YouTube videos for the purpose of social and political activism: they can be shared easily, quickly, and effectively through a variety of mechanisms, including other forms of social media, email, and print media.
The article "The Rules of Engagement: Comparing Two Social Protest Movements on YouTube" compares how two disparate political movements used YouTube to define and advance their goals. The study shows that social media activism resulted in differing degrees of popularity and engagement, perhaps related to the content of the videos and to the different online environments in which they appear.
"As YouTube matures, and additional social networking tools evolve, it is interesting to note how these tools may be used by individual citizens as well as political activists to advance their goals," says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior, and Social Networking, from the Interactive Media Institute, San Diego, CA.
###
About the Journal
Cyberpsychology, Behavior, and Social Networking is a peer-reviewed journal published monthly online with Open Access options and in print that explores the psychological and social issues surrounding the Internet and interactive technologies, plus cybertherapy and rehabilitation. Complete tables of content and a sample issue may be viewed on the Cyberpsychology, Behavior, and Social Networking website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Games for Health Journal, Telemedicine and e-Health, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
[
| E-mail
Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Is YouTube a driver for social movements like Occupy Wall Street?
PUBLIC RELEASE DATE:
29-Oct-2013
[
| E-mail
]
Share
Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, October 29, 2013Social media such as YouTube videos provide a popular and flexible venue for online activism. How two different social protest movementsOccupy Wall Street and the Proposition 8 same sex marriage initiativeutilized YouTube, and their success in engaging activists are explored in an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cyberpsychology, Behavior, and Social Networking website.
Emily Vraga, PhD and coauthors from George Mason University (Fairfax, VA), Georgetown University (Washington, DC), University of Wisconsin-Madison, and University of Southern California (Los Angeles, CA) emphasize an important advantage of YouTube videos for the purpose of social and political activism: they can be shared easily, quickly, and effectively through a variety of mechanisms, including other forms of social media, email, and print media.
The article "The Rules of Engagement: Comparing Two Social Protest Movements on YouTube" compares how two disparate political movements used YouTube to define and advance their goals. The study shows that social media activism resulted in differing degrees of popularity and engagement, perhaps related to the content of the videos and to the different online environments in which they appear.
"As YouTube matures, and additional social networking tools evolve, it is interesting to note how these tools may be used by individual citizens as well as political activists to advance their goals," says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior, and Social Networking, from the Interactive Media Institute, San Diego, CA.
###
About the Journal
Cyberpsychology, Behavior, and Social Networking is a peer-reviewed journal published monthly online with Open Access options and in print that explores the psychological and social issues surrounding the Internet and interactive technologies, plus cybertherapy and rehabilitation. Complete tables of content and a sample issue may be viewed on the Cyberpsychology, Behavior, and Social Networking website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Games for Health Journal, Telemedicine and e-Health, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
[
| E-mail
Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Sticking together! After denying reports of a cheating scandal earlier this month, Ramona Singer and husband Mario Singer showed a united front over the weekend while visiting daughter Avery at Emory University in Atlanta. The Real Housewives of New York City star, 56, shared photos of their trip and special "family time" on Twitter.
"On our way to Atlanta visiting Avery for parents weekend. We brought a surprise for her, Coco!!" Ramona captioned a selfie with Mario, 60, and their dog Coco on Thursday, Oct. 24.
On Saturday, she shared a group photo of Avery reuniting with family and wrote, "Loving our time with @averysinger. Mario even brought Coco as a surprise for her #4specialday #familytime."
"This has been such a special weekend," she tweeted the following day. "Enjoying our last few hours before heading back to NYC." Before getting their flight home, Ramona shared one last photo of the threesome posing together with the caption, "Such a special family weekend with @averysinger and Mario in Atlanta. We miss her."
Ramona Singer and husband Mario visited daughter Avery at college in Atlanta. Credit: Courtesy Ramona Singer
Earlier this month, The New York Post's Page Six alleged that Mario had had an affair and impregnated a young New York socialite. Ramona denied the claims to Hollywood Life that same day, saying, "It's not true."
The spouses of 27 years seem to be doing well despite the scandal. Ramona tweeted on Oct. 28, "Mario and I are matching this #Halloween! Guess what we will be . . . Hint: we'll be wearing masks."
Reports of the USS Zumwalt's christening being delayed until next spring have been greatly exaggerated. In a surprise move, the US Navy instead launched the next-generation destroyer from its berth in Bath, Maine early this morning.
Queen's University in 6m bid to find new Cystic Fibrosis treatments
PUBLIC RELEASE DATE:
29-Oct-2013
[
| E-mail
]
Share
Contact: Anne-Marie Clarke comms.officer@qub.ac.uk 44-028-909-75320 Queen's University Belfast
Queen's University Belfast is a lead partner in a new 6 million global research program to develop new ways to treat Cystic Fibrosis
Queen's University Belfast is a lead partner in a new 6 million (euro) global research programme to develop new ways to treat Cystic Fibrosis.
Affecting more than 10,000 people in the UK, Cystic Fibrosis (CF) is one of the most common life-threatening inherited diseases. Symptoms include repeated chest infections, the major cause of death for patients.
The new global programme, known as CF Matters, aims to develop personalised antibiotic treatments for these chest infections. The work could revolutionise the practice of antibiotic prescription and limit resistance to the drugs globally.
The study brings together renowned CF clinicians and scientists from 12 academic institutions and hospitals across Europe and the USA. It is led by University College Cork with Queen's as a lead partner. It will involve lab-based research and clinical trials with 252 patients in seven countries, including around 40 in Northern Ireland.
Queen's lead on the study is Professor Stuart Elborn, Director of Queen's Centre for Infection and Immunity. An internationally recognised CF expert, he led the original trial for a drug which has now been approved for use by CF patients with the G551D gene mutation or 'Celtic Gene'. The drug Ivacaftor, also known as Kalydeco, treats the root cause of CF for people with the Gene.
Professor Elborn said: "When patients have a flare-up they are treated with several antibiotics but it isn't always effective and can lead to antibiotic resistance. In this study we will use molecular next generation DNA sequencing methods to detect all the bacteria present in the sputum of CF patients and use this knowledge to determine what antibiotics should be used in individual patients.
"This personalised antibiotic treatment will be compared with standard therapy for CF patients. We will determine the patient's immune response to all the different bacteria present in the sputum. Using models of infection we will also discover the effect of these bacteria on lung inflammation and infection. The overall impact will be to determine if all bacteria present contribute significantly to lung infection in CF patients and subsequently identify the most effective antibiotic treatment for patients infected with these bacteria."
The study will involve a team of scientists from Queen's Centre for Infection and Immunity including Professor Cliff Taggart, Dr Rebecca Ingram and Dr Sinad Weldon and Dr Michael Tunney from the School of Pharmacy.
They will collaborate with Dr Damian Downey, Co-Director of the Regional Adult Cystic Fibrosis Centre in the Belfast Health and Social Care Trust. Dr Downey said: "This important collaborative study with our colleagues in Queen's University will investigate the use of directed antibiotic therapy to treat lung infections. The aim of a more focused treatment plan is to limit the damage that occurs to the lung."
The CF Matters grant comes just weeks after Queen's work on managing Bronchiectasis, another chronic lung condition affecting thousands of people in the UK, was published in leading scientific journals.
The three papers by Dr Michael Tunney from Queen's School of Pharmacy and Professor Elborn, address key issues in the management of the condition, including the detection of bacteria that cause lung infection and how long-term antibiotic use to treat Bronchiectasis can result in antibiotic resistance.
Commenting on the work, Dr Tunney said: "We found that large numbers of different types of bacteria were present both when bronchiectasis patients were stable, and during a lung infection. The results clearly demonstrate that routine diagnostic techniques do not detect many of these bacteria.
"Further studies are required to better understand the relationship between the presence of the bacteria found in the lungs of Bronchiectasis patients and the severity of the condition. More research is also needed into the effects of long-term antibiotic use and development of antimicrobial resistance."
###
For more information on the Centre visit http://www.qub.ac.uk/research-centres/CentreforInfectionandImmunity
Media inquiries to Anne-Marie Clarke at Queen's University Communications Office.
Tel: +44 (0)28 9097 5320 or email: comms.officer@qub.ac.uk
Notes to editors:
Professor Stuart Elborn is available for interview
Queen's University has been given 1.36m from the overall grant awarded by the European Union's Seventh Framework Programme.
The full trial name is Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified CF MATTERS
The study is led by Dr Barry Plant at University College Cork. Research partners include Queen's University Belfast, Universit Parus Descartes (France), University of Dundee (Scotland), University of Washington (USA), University of Heidelberg (Germany), Teagasc Food Research Centre (Ireland), Clininfo SA (France), GABO (Germany), Papworth Hospital (UK), University Hospital Leuven (Belgium), Assistance Publique-Hopitaux de Paris (France).
The results of the study will be reviewed by an expert panel who will then develop a tailored treatment plan for each patient. The analysis of all the bacteria present will pave the way for more effective therapeutic regimes and ultimately contribute to the development of personalised treatment for CF patients.
[
| E-mail
Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Queen's University in 6m bid to find new Cystic Fibrosis treatments
PUBLIC RELEASE DATE:
29-Oct-2013
[
| E-mail
]
Share
Contact: Anne-Marie Clarke comms.officer@qub.ac.uk 44-028-909-75320 Queen's University Belfast
Queen's University Belfast is a lead partner in a new 6 million global research program to develop new ways to treat Cystic Fibrosis
Queen's University Belfast is a lead partner in a new 6 million (euro) global research programme to develop new ways to treat Cystic Fibrosis.
Affecting more than 10,000 people in the UK, Cystic Fibrosis (CF) is one of the most common life-threatening inherited diseases. Symptoms include repeated chest infections, the major cause of death for patients.
The new global programme, known as CF Matters, aims to develop personalised antibiotic treatments for these chest infections. The work could revolutionise the practice of antibiotic prescription and limit resistance to the drugs globally.
The study brings together renowned CF clinicians and scientists from 12 academic institutions and hospitals across Europe and the USA. It is led by University College Cork with Queen's as a lead partner. It will involve lab-based research and clinical trials with 252 patients in seven countries, including around 40 in Northern Ireland.
Queen's lead on the study is Professor Stuart Elborn, Director of Queen's Centre for Infection and Immunity. An internationally recognised CF expert, he led the original trial for a drug which has now been approved for use by CF patients with the G551D gene mutation or 'Celtic Gene'. The drug Ivacaftor, also known as Kalydeco, treats the root cause of CF for people with the Gene.
Professor Elborn said: "When patients have a flare-up they are treated with several antibiotics but it isn't always effective and can lead to antibiotic resistance. In this study we will use molecular next generation DNA sequencing methods to detect all the bacteria present in the sputum of CF patients and use this knowledge to determine what antibiotics should be used in individual patients.
"This personalised antibiotic treatment will be compared with standard therapy for CF patients. We will determine the patient's immune response to all the different bacteria present in the sputum. Using models of infection we will also discover the effect of these bacteria on lung inflammation and infection. The overall impact will be to determine if all bacteria present contribute significantly to lung infection in CF patients and subsequently identify the most effective antibiotic treatment for patients infected with these bacteria."
The study will involve a team of scientists from Queen's Centre for Infection and Immunity including Professor Cliff Taggart, Dr Rebecca Ingram and Dr Sinad Weldon and Dr Michael Tunney from the School of Pharmacy.
They will collaborate with Dr Damian Downey, Co-Director of the Regional Adult Cystic Fibrosis Centre in the Belfast Health and Social Care Trust. Dr Downey said: "This important collaborative study with our colleagues in Queen's University will investigate the use of directed antibiotic therapy to treat lung infections. The aim of a more focused treatment plan is to limit the damage that occurs to the lung."
The CF Matters grant comes just weeks after Queen's work on managing Bronchiectasis, another chronic lung condition affecting thousands of people in the UK, was published in leading scientific journals.
The three papers by Dr Michael Tunney from Queen's School of Pharmacy and Professor Elborn, address key issues in the management of the condition, including the detection of bacteria that cause lung infection and how long-term antibiotic use to treat Bronchiectasis can result in antibiotic resistance.
Commenting on the work, Dr Tunney said: "We found that large numbers of different types of bacteria were present both when bronchiectasis patients were stable, and during a lung infection. The results clearly demonstrate that routine diagnostic techniques do not detect many of these bacteria.
"Further studies are required to better understand the relationship between the presence of the bacteria found in the lungs of Bronchiectasis patients and the severity of the condition. More research is also needed into the effects of long-term antibiotic use and development of antimicrobial resistance."
###
For more information on the Centre visit http://www.qub.ac.uk/research-centres/CentreforInfectionandImmunity
Media inquiries to Anne-Marie Clarke at Queen's University Communications Office.
Tel: +44 (0)28 9097 5320 or email: comms.officer@qub.ac.uk
Notes to editors:
Professor Stuart Elborn is available for interview
Queen's University has been given 1.36m from the overall grant awarded by the European Union's Seventh Framework Programme.
The full trial name is Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified CF MATTERS
The study is led by Dr Barry Plant at University College Cork. Research partners include Queen's University Belfast, Universit Parus Descartes (France), University of Dundee (Scotland), University of Washington (USA), University of Heidelberg (Germany), Teagasc Food Research Centre (Ireland), Clininfo SA (France), GABO (Germany), Papworth Hospital (UK), University Hospital Leuven (Belgium), Assistance Publique-Hopitaux de Paris (France).
The results of the study will be reviewed by an expert panel who will then develop a tailored treatment plan for each patient. The analysis of all the bacteria present will pave the way for more effective therapeutic regimes and ultimately contribute to the development of personalised treatment for CF patients.
[
| E-mail
Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Share
